Loading stock…

Sun Pharmaceutical Industries Limited (SUNPHARMA) Stock Verdict & Ratings | Investment Bastion

Stock Verdict·Updated 1d ago

Sun Pharmaceutical Industries Limited

SUNPHARMAMarket cap $45BPrice $18.5

Country🇮🇳India

SectorHealthcare

IndustryPharmaceuticals

Makes generic drugs and specialty medicines, ranking as India's largest pharmaceutical company by market value. Supplies medications to over 100 countries and owns manufacturing facilities across five continents.

In Bastion Portfolios?

52W Return-2%Global Market +16%?

01Key Ratings

How does this stock score across Bastion factors?

Growth

Historical Revenue

Rev CAGR (3y)+5%5

Revenue Forecast

Rev CAGR (1y)+8%5

Rev CAGR (3y)+11%7

Rev CAGR (5y)+9%7

Earnings Forecast

EPS Growth Y+1+10%6

EPS Growth Y+2+19%8

EPS Growth Y+3+18%8

Quality

Margins

EBIT Margin23%8

Net Income Margin20%8

Free Cash Flow Margin15%7

Debt

Net Debt/EBITDA-1.710

Efficiency

ROE16%7

ROAna–

Earnings Stability88

GEAR+STRONG84

Overall rating across all five factors

Value

Price Multiples

P/E Ratio (Forward)332

P/E Ratio (Forward 3y)242

P/BV5.23

EV Multiples

EV/EBITDA Fwd222

EV/EBIT Fwd263

Yield

Free Cash Flow Yield2.0%4

Dividend Yieldna–

Momentum

Short term

1 month return-5%5

3 month return-6%5

YTD return+5%6

Mid term

Price vs 52wHigh87%7

1 year return+9%6

Long term

3 year return+64%6

5 year return+129%8

Risk Shield

100

Price Risk

Beta0.110

Volatility19%10

Free Cash Flow

Free Cash Flow Margin15%7

Free Cash Flow Yield2.0%4

Quality

ROCE32%10

Earnings Stability88

Net Debt/EBITDA-1.710

02Growth

Is it actually growing, and how fast?

SUNPHARMASun Pharmaceutical Industries

Revenue FY26$6.3B

GROWTH RATING↗

AVERAGE63 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+5%5

Revenue, next 1Y+8%5

Revenue, next 3Y, CAGR+11%7

Revenue, next 5Y, CAGR+9%7

EARNINGS FORECAST▾SCORE

EPS growth, FY27E+10%6

EPS growth, FY28E+19%8

EPS growth, FY29E+18%8

GROWTH ASSESSMENT

STRENGTHS

Revenue grew 5%/yr over the last 3 years and is set to grow 11%/yr from here.

The runway holds up: revenue is set to grow 9%/yr over five years.7/10

Earnings are set to grow faster than sales (EPS about 18%/yr vs revenue 11%/yr), so margins should widen.

WATCH

A mid-pack grower, ahead of 63% of companies worldwide.

Revenue is set to grow 11%/yr over the next 3 years, a little ahead of the market.6/10

WEAKNESSES

None flagged.

BOTTOM LINE

Reaccelerating Grower

A middle-of-the-pack grower that's speeding up.

03Price Momentum

Is the market behind it right now?

SUNPHARMASun Pharmaceutical Industries

Total return Current90.1%

Price return Current74.7%

MOMENTUM RATING↗

AVERAGE60 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-5%5

3-month return-6%5

YTD return+5%6

MID & LONG-TERM▾SCORE

% of 52-week high87%7

1-year return+9%6

3-year return+64%6

5-year return+129%8

MOMENTUM ASSESSMENT

STRENGTHS

Strong long-term results. Long-term holders have seen +64% over three years and +129% over five, ahead of 60% of the market.

It's up 9% over the past year, but 13% below its 52-week high. That is clearly ahead of the market.

WATCH

Returns sit at the market level over the past month (-5%), over three months (-6%) and so far this year (+5%).

WEAKNESSES

None flagged.

BOTTOM LINE

Steady Compounder

Dependable multi-year returns with a calmer near-term tape. A reliable long-term trend rather than a short-term breakout.

04Value

Are you paying a fair price for it?

Stop guessing on Sun Pharma. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

Loading charts…

02Growth

Is it actually growing, and how fast?

SUNPHARMASun Pharmaceutical Industries

Revenue FY26$6.3B

GROWTH RATING↗

AVERAGE63 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+5%5

Revenue, next 1Y+8%5

Revenue, next 3Y, CAGR+11%7

Revenue, next 5Y, CAGR+9%7

EARNINGS FORECAST▾SCORE

EPS growth, FY27E+10%6

EPS growth, FY28E+19%8

EPS growth, FY29E+18%8

GROWTH ASSESSMENT

STRENGTHS

Revenue grew 5%/yr over the last 3 years and is set to grow 11%/yr from here.

The runway holds up: revenue is set to grow 9%/yr over five years.7/10

Earnings are set to grow faster than sales (EPS about 18%/yr vs revenue 11%/yr), so margins should widen.

WATCH

A mid-pack grower, ahead of 63% of companies worldwide.

Revenue is set to grow 11%/yr over the next 3 years, a little ahead of the market.6/10

WEAKNESSES

None flagged.

BOTTOM LINE

Reaccelerating Grower

A middle-of-the-pack grower that's speeding up.

03Price Momentum

Is the market behind it right now?

SUNPHARMASun Pharmaceutical Industries

Total return Current90.1%

Price return Current74.7%

MOMENTUM RATING↗

AVERAGE60 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-5%5

3-month return-6%5

YTD return+5%6

MID & LONG-TERM▾SCORE

% of 52-week high87%7

1-year return+9%6

3-year return+64%6

5-year return+129%8

MOMENTUM ASSESSMENT

STRENGTHS

Strong long-term results. Long-term holders have seen +64% over three years and +129% over five, ahead of 60% of the market.

It's up 9% over the past year, but 13% below its 52-week high. That is clearly ahead of the market.

WATCH

Returns sit at the market level over the past month (-5%), over three months (-6%) and so far this year (+5%).

WEAKNESSES

None flagged.

BOTTOM LINE

Steady Compounder

Dependable multi-year returns with a calmer near-term tape. A reliable long-term trend rather than a short-term breakout.

04Value

Are you paying a fair price for it?

Stop guessing on Sun Pharma. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community